0.190
0.00 (0.00%)
| Previous Close | 0.190 |
| Open | 0.192 |
| Volume | 23,095 |
| Avg. Volume (3M) | 340,935 |
| Market Cap | 85,091,880 |
| Price / Sales | 4.90 |
| Price / Book | 2.32 |
| 52 Weeks Range |
| Profit Margin | -83.97% |
| Operating Margin (TTM) | -136.14% |
| Diluted EPS (TTM) | -0.030 |
| Quarterly Revenue Growth (YOY) | 147.00% |
| Total Debt/Equity (MRQ) | 9.72% |
| Current Ratio (MRQ) | 2.17 |
| Operating Cash Flow (TTM) | -6.66 M |
| Levered Free Cash Flow (TTM) | -7.32 M |
| Return on Assets (TTM) | -24.29% |
| Return on Equity (TTM) | -33.42% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (AU) | Mixed | Mixed |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | MICROBA FPO [MAP] | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are; Testing Services and Supplements which derives key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 54.55% |
| % Held by Institutions | 27.85% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |